K63-linked ubiquitination of DYRK1A by TRAF2 alleviates Sprouty 2-mediated degradation of EGFR

Pengshan Zhang1,2,3, Zhe Zhang4, Yinkun Fu2, Ying Zhang2, Michael P. Washburn5,6, Laurence Florens7, Min Wu7, Chen Huang1,2,3, Zhaoyuan Hou1,2,3 and Man Mohan2,4

© The Author(s) 2021

INTRODUCTION
Dual specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) is a member of the CMGC (including cyclin-dependent kinases (CDKs), mitogen-activated protein kinases (MAP kinases), glycogen synthase kinases (GSK) and CDK-like kinases) group of serine/threonine kinases [1]. Owing to its localization within the Down Syndrome Critical Region on chromosome 21, and due to its dosage-sensitive functions, it is believed to contribute to Down syndrome phenotypes [2]. DYRK1A is implicated in embryonic development and cellular growth, and it regulates the balance between proliferation and differentiation in neural progenitors, in developing nervous system [2, 3]. DYRK1A’s function is dosage sensitive and alterations in its expression levels lead to pathology [4, 5]. A number of heterozygous mutations in DYRK1A in or near the kinase domain are associated with DYRK1A syndrome, which exhibit growth retardation, microcephaly, and intellectual disability [4, 5]. Similar phenotypes were observed in heterozygous DYRK1A mice [6, 7]. Growth retardation and a small brain phenotype is also observed due to loss of DYRK1A homologs in Drosophila and zebrafish [8, 9]. Reduced brain size in DYRK1A loss-of-function models is caused by a reduction in the number of neurons in some parts of the brain, whereas other areas see an increased number of neurons [10]. DYRK1A is shown to phosphorylate several proteins involved in neuronal synaptic transmission, including Dynamin 1, Amphiphysin 1, and Synaptopjanin 1 [2, 11-14], and functions in synaptic vesicle endocytosis [11]. Overall, these studies indicate a function of DYRK1A in neuronal development.

Down syndrome patients exhibit an increased incidence of leukemia and a three-copy Dyrk1a mouse model develops acute megakaryoblastic leukemia [15]. In the gliomas, high expression of DYRK1A correlates with epidermal growth factor receptor (EGFR) expression. DYRK1A prevents endocytotic degradation of EGFR through phosphorylation of the EGFR-signaling modulator Sprouty 2 (SPRY2) and DYRK1A inhibition leads to reduced glioma growth [16, 17]. These observations implicate DYRK1A in tumorigenesis.

Over the past two decades, a large number of DYRK1A substrates located in various subcellular structures, including the nucleus, cytoplasm, cytoskeleton, and vesicles, have been identified, suggesting a wide variety of cellular functions for DYRK1A [18]. A number of studies have shown that DYRK1A associates with and phosphorylates multiple proteins found in the vesicles, and affects the synaptic vesicle, EGFR, and Transferrin endocytosis [2]. The regulation of DYRK1A localization and function in the vesicles, however, is not clear.

Tumor necrosis factor receptor (TNFR)-associated factor 2 (TRAF2) is an adaptor protein in the TNF-induced signaling
pathway. Upon ligand binding to TNFR1 and TNFR2, TRAF2 is recruited to the plasma membrane and promotes the activation of canonical nuclear factor-κB (NF-κB) pathway and JNK/p38 pathways [19]. TRAF2 harbors a RING domain, which primarily mediates K63-linked ubiquitination of substrates [20–23], and a TRAF domain, which has scaffolding activity [24]. Recent reports indicate that TRAF2 is also involved in other pathways, including activation of NF-κB pathway induced by nucleotide-binding oligomerization domain-like receptors, in a RIG-I-like receptor-mediated antiviral response pathway and cytokine receptor signaling [25, 26]. Further, some recent studies have reported TRAF2 to be upregulated in multiple cancer types including the glioma and can serve as prognostic biomarker [27–29].

In this study, we have identified TRAF2 as an interaction partner of DYRK1A. We found that TRAF2 mediates K63-linked ubiquitination of DYRK1A and causes its translocation into vesicles, where DYRK1A interacts with and phosphorylates SPRY2. This TRAF2–DYRK1A–SPRY2 axis regulates the stability of EGFR, which could be significant in the EGFR-dependent glioblastoma or other cancers.

MATERIALS AND METHODS

Plasmids
The human TRAF2 cDNA was subcloned into a pcMV vector with an N-terminal Myc tag to generate Myc-TRAF2. The mouse Trf2 cDNA was subcloned into pCDH-CMV lentivector with an N-terminal hemagglutinin (HA) tag to generate HA-Trf2. pcDNA3.1Flag-Dyrk1a plasmid has been previously described [30]. Dyrk1a cDNA was also subcloned into a doxycycline-inducible expression lentivector pLUT (kindly gifted by Dr. Zhaoyuan Hou from Shanghai Jiaotong University School of Medicine, Shanghai, China) with an N-terminal Flag tag, pH-Flag-ub-K48-only and pH-Flag-ub-K63-only plasmids were kindly gifted by Dr. Xuemei Tong (Shanghai Jiaotong University School of Medicine, Shanghai, China), and we replaced the Flag tag with Myc tag. All Myc-TRAF2 truncations, Flag-Dyrk1a mutants, and Myc-ub mutants were made by using site-directed mutagenesis procedures following the manufacturer’s protocol (Toyobo, Japan). The pHClO04-SPRY2-2VS expression plasmid (cDNA BC017545.1) was obtained from Thermo Fisher. All the constructs were confirmed by DNA sequencing. Lentiviral vectors to silence human DYRK1A has been previously described [30]. Short hairpin RNA (shRNA) targeting human TRAF2 or mouse Dyrk1a were from GenePharma Co., Ltd (Shanghai, China). The sequences to silence human DYRK1A were shDYRK1A-1, 5'-GGATTTACCAGCCCGGTCCAGGC-3' and shDYRK1A-2, 5'-TGACCAAGTGGTGTCTGCAC-3'. The sequences to silence human TRAF2 were shTRAF2-1, 5'-CCAGCTGACATCCACACCAT-3' and shTRAF2-2, 5'-TGGACCAAGA CAGAGTGA-3'.

Cell culture, viral production, and infection
HEK293, HEK293T, SH-SYSY, NIH3T3, U251, and A127 cells were obtained from the American Type Culture Collection. All cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Gibco), 50 U/ml penicillin, and 50 μg/ml streptomycin (Hyclone). All cell lines were maintained at 37 °C under 5% CO2 in a humidified chamber. For viral production, lentiviral vectors and packaging plasmids (psPAX and pMD2.G plasmids) were transfected into HEK293T cells with polyethyleneimine (PEI; 23966, Polysciences) or Lipofectamine 3000 (L3000-008, Invitrogen). Two days later, cell culture supernatant containing lentiviruses were transfected into HEK293T cells overnight.

Cell proliferation, colony formation assay, and wound-healing assay
For cell proliferation analysis, cells were plated at 100,000 cells per well of 6-well plates and then cell numbers were counted with trypan blue exclusion staining at day 1, 2, and 3 after plating. For colony formation, cells in single-cell suspension were plated into 6 cm dishes at a density of 500 cells for 14 days, then the growth medium was removed, and each dish was washed with phosphate-buffered saline (PBS), the colonies were fixed with 4% paraformaldehyde, and stained with 0.1% crystal violet. Excess crystal violet was washed off with double-distilled water. Cell images were captured and the numbers of cells were counted. Experiments were performed in triplicate. Wound-healing assays were performed as previously described [31].

Separation of subcellular compartments
Cells in the dishes were rinsed twice with PBS and lysed in 0.5% Triton X-100 lysis buffer (0.5% Triton X-100, 20 mM HEPES pH 7.4, 150 mM NaCl, 2 mM EDTA) supplemented with protease and phosphatase inhibitors (Sigma, USA), and incubated on ice for 30 min. Lysates were centrifuged at 17,000 × g, 4 °C for 15 min, and supernatant taken as 0.5% Triton X-100 insoluble fraction. The pellets were washed three times in 0.5% Triton X-100 lysis buffer and resuspended in 2% SDS lysis buffer (2% SDS, 50 mM Tris-HCl pH 6.8, 6% glycerol), heated at 95 °C for 10 min, and sonicated. Lysates were centrifuged at 17,000 × g for 15 min and the supernatant taken as 0.5% Triton X-100 insoluble fraction.

Antibodies
Antibodies used in the study were as follows: anti-Flag (F3165/F7425, Sigma), anti-Myc (9811/71D10, Cell Signaling Technology (CST)), anti-HA (16B12, Biologend and H6908, Sigma), anti-TRAF2 (sc-136999, Santa Cruz), anti-Rab5 (sc-46692, Santa Cruz), anti-Rab7 (sc-376362, Santa Cruz), anti-SPROUTY2 (sc-100862, Santa Cruz/ab5670, Abcam), anti-EGFR (sc-377346, Santa Cruz), anti-p-EGFR (sc-44411, CST), anti-Actin (sc-80676, Abcam), anti-UBB (sc-5368, Sigma), anti-Ser (sc-81514, Santa Cruz, anti-Thr (sc-37627, Santa Cruz), anti-UBiquitin (sc-8017, Santa Cruz), anti-β-Actin (AC026, Abclonal), anti-GFP (AE011, Abclonal), anti-glutathione S-transferase (GST) (2622 S, CST), anti-EGFR (R960-25, Thermo Fisher and 30801ES10, Yeasen), anti-Mouse/Rabbit IgG-peroxidase secondary antibody (A0545/A9044, Sigma), anti-Mouse IgG (light chain specific)-peroxidase secondary antibody (115-005-174, Jackson), and anti-DYRK1A polyclonal antibody has been previously described [30].

Immunoblotting
In the dishes were rinsed twice with PBS, then cells were scrapped into radioimmunoprecipitation assay lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.25% sodium deoxycholate, 0.1% SDS, 1 mM EDTA supplemented with protease and phosphatase inhibitors) followed by 30 min on ice, or scraped into 2% SDS lysis buffer (2% SDS, 50 mM Tris-HCl pH 6.8, 6% glycerol) followed by heating at 95 °C for 10 min. Lysates were sonicated and centrifuged at 17,000 × g, 4 °C for 15 min. Protein concentration was measured with BCA Protein Assay Kit (23227, Thermo Fisher). Protein samples were separated on SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes. After blocking, blots were incubated with primary antibodies at 4 °C overnight, then incubated with secondary antibodies labeled with horseradish peroxidase at room temperature (RT) for 1 h and the signals were detected using the ECL Kit (WBKLS0100, Millipore). Western blot signals were quantified with Image J software.

Co-immunoprecipitation and GST pulldown
Cells in the dishes were rinsed twice with PBS, then cells were scrapped into IP lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 2 mM EDTA) supplemented with phosphatase and protease inhibitors (Sigma, USA) and incubated on ice for 30 min. Lysates were centrifuged at 17,000 × g, 4 °C for 15 min, then the supernatant (soluble fraction) was reserved. The pellets were suspended in the same lysis buffer containing 60 mM N-octylglucoside (Sangon Biotech, China) on ice for 30 min. Extracts were spun down at 17,000 × g, 4 °C for 15 min and the supernatant (insoluble fraction) was reserved. Then soluble fraction and insoluble fraction were mixed and incubated with anti-Flag M2 affinity gel (A2220, Sigma) or anti-Myc agarose affinity gel (Sigma, USA) for 4 h at 4 °C, or incubated with protein A or protein A/G beads (Millipore, USA) and anti-TRAF2/anti-DYRK1A/anti-V5 antibody overnight at 4 °C. Then beads were washed four times and eluted with 2× SDS loading buffer. Samples were subjected to immunoblotting.

The GST pull-down assay were described previously [32]. GST-TRAF2 was expressed in Escherichia coli BL21 cells, which were induced by isopropyl-β-D-thiogalactoside (IPTG), and purified by Glutathione Sepharose beads (17-0756-01, GE Healthcare). For the in vitro binding assays, GST-TRAF2 protein was mixed with Flag-DYRK1A protein purified from HEK293T cells overnight.
Large-scale Flag affinity purification and MudPIT analysis

Approximately 10^5 cells for each cell line were collected and washed with PBS. Cells were swollen for 15 min in hypertonic buffer (Buffer A: 10 mM Hepes pH 7.9, 1.5 mM MgCl_2, 10 mM KCl, 0.5 mM dithiothreitol) freshly supplemented with protease inhibitor cocktail (P8340, Sigma). Swollen cells were dounced 20 times in a Wheaton dounce homogenizer till about 90% cells were lysed (as observed in a microscope). Lysate is then centrifuged at 25,000 x g for 20 min, to pellet nuclei and cell debris. To the supernatant (S100), 0.11 volume of Buffer B (0.3 M Hepes pH 7.9, 1.4 M KCl, and 0.03 M MgCl_2) was added and cleared by centrifuging at 100,000 x g, 4°C for 1 h. The supernatant was treated as cytoplasmic extract and Flag-affinity was performed by incubating Flag beads for 3-4 h. Beads were then washed with Flag wash buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl_2, 300 mM NaCl, 10 mM KCl, 0.2% Triton X-100) three times and then eluted two times in elution buffer (200 μg/ml Flag peptide, 10 mM HEPES pH 7.9, 0.1 M NaCl, 1.5 mM MgCl_2, 0.05% Triton X-100). Eluates were analyzed by silver staining and western blotting. Trichoracetic acid-precipitated protein mixtures from the Flag-X-100). Eluates were analyzed by silver staining and western blotting.

Identi(Thermo Fisher Scientific) 1100 series high-performance liquid chromatography pump and a 150 mM NaCl, 0.5 mM dithiothreitol) three times. Bands in the DYRK1A overexpression lane. Further, we co-

RESULTS

DYRK1A interacts with E3 ubiquitin ligase TRAF2

We have previously generated stable HEK293T cell lines transformed with inducible Flag-DYRK1A [30, 33]. From these cells, we affinity-purified Flag-DYRK1A from cytoplasmic fractions (S100) and analyzed the eluates by SDS-PAGE and silver staining (Fig. 1A). To identify the interacting proteins, we performed MudPIT analysis and observed enrichment of a number of proteins including previously known interactors including DCAF7, ARIP4 (Fig. 1B) [34–36]. Among the novel interactions of DYRK1A, we found TRAF2, an E3 ubiquitin ligase for both K48- and K63-linked ubiquitination. To confirm the interaction between TRAF2 and DYRK1A, we co-overexpressed Flag-DYRK1A and Myc-TRAF2. To prevent the IgG heavy chain from obscuring the TRAF2 signal, which migrates around 50 kDa in SDS-PAGE, we utilized a secondary antibody recognizing only the light chain. We observed that the overexpressed Flag-DYRK1A pulled down overexpressed Myc-TRAF2 (Fig. 1C). Conversely, overexpressed Myc-TRAF2 pulled down Flag-DYRK1A (Fig. 1D). Interestingly, overexpression of TRAF2 caused the appearance of several new slower migrating bands in the DYRK1A overexpression lane. Further, we co-

Immunofluorescence

Cells were plated onto pre-coated glass coverslips in a 24-well plate. After 36–48 h of transfection of plasmids as indicated using PEI or Lipofectamine 3000, cells were fixed with 4% paraformaldehyde for 15 min. After being washed three times with PBS, the cells were permeabilized with 0.2% Triton X-100 at RT for 10 min and then washed three times with PBS. Blocking was performed with 5% normal goat serum for 1 h at RT, followed by incubation with primary antibodies at 4°C overnight. After being washed three times with PBS, the samples were treated with Alexa Fluor® 488-conjugated (A11011, Invitrogen) and Alexa Fluor® 568-conjugated secondary antibodies (A11011, Invitrogen) for 1 h at RT. After being washed with PBS, the samples were treated with DAPI (D3571, Invitrogen) for 5 min at RT and washed with PBS three times. Finally, the coverslips were placed on glass slides and sealed with nail polish. The fluorescence staining was detected with ZEISS 710 confocal laser scanning microscope. Images were processed and analyzed with Zen software.

In vivo ubiquitination assay

HEK293 cells were transfected with the indicated plasmids for 36–48 h. After rinsing twice with PBS, cells were scraped into 100 μl of lysis buffer (2% SDS, 150 mM NaCl, 20 mM Tris-HCl, pH 8.0), heated for 10 min at 95°C, diluted with the same lysis buffer lacking SDS to reduce the SDS concentration to 0.2%, and sonicated mildly on ice. Lysates were centrifuged at 17,000 x g, 4°C for 15 min. Then the supernatant was incubated with anti-Flag M2 affinity gel (A2200, Sigma) or incubated with protein A (Millipore, USA) and anti-DYRK1A antibody overnight at 4°C. Beads were washed three times and boiled with 2x SDS loading buffer for 10 min. Samples were subjected to SDS-PAGE and analyzed by western blotting using the indicated antibodies.

In vitro ubiquitination assay

E. coli BL21 cells were transfomed with pGEX-4T-1 or pGEX-4T-1-TRAF2 plasmids, induced by IPTG, and purified by Glutathione Sepharose beads (17-0756-01, GE Healthcare). Flag-DYRK1A was overexpressed in HEK293T cells, cultured for 48 h post transfection, and purified. In vitro ubiquitination assays were performed with the following components: 1 μg purified GST-TRAF2, 2 μg purified Flag-DYRK1A, 100 μM HA-ubiquitin, 100 mM E1, 1 μM E2 enzymes (UbH5a/b/c and UbC13/UbV1a (Boston Biochem, Cambridge, MA, USA), 1 mM ATP in Ubiquitin conjugation reaction buffer. The reaction was run for 3 h at 37°C. After that, the reaction volume was adjusted to 150 μl, dissociated by heating at 95°C in 1% SDS/sv, and diluted 1:10 with IP buffer (20 mM Tris-HCI pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 2 mM EDTA, phosphatase and protease inhibitors). The diluted reactions were incubated with anti-Flag M2 affinity gel (A2220, Sigma) overnight at 4°C. Then beads were washed six times and eluted with 2x SDS loading buffer. Samples were subject to western blotting analysis.

Statistical analysis

All the statistical data were presented as the means ± SD from at least three independent experiments. The statistical significance of differences between groups was analyzed using the GraphPad Prism software. Differences between individual groups were analyzed using the Student’s t-test. A p-value < 0.05 was considered significant.

Mass spectrometry data set accessibility

Mass spectrometry data files are available from Massive at ftp://massive.ucsd.edu/MSV000085815/ and ProteomeXchange (PXD002533). Original data underlying this manuscript can be accessed from the Stowers Original Data Repository at http://www.stowers.org/research/publications/libpp-1542.
DYRK1A bears a conserved “PVQE” TRAF2-binding site
To analyze the domain(s) responsible for interaction between TRAF2 and DYRK1A, we constructed three Myc-TRAF2 truncations as follows: (1) ring deletion (ΔRING), (2) zinc finger domain truncation (ΔZinc Fingers), and (3) TRAF domain truncation (ΔTRAF) (Fig. 2A). Full-length TRAF2, ΔRING, and ΔZinc Fingers but not ΔTRAF interacted with DYRK1A in co-immunoprecipitation experiments (Fig. 2B). In addition, overexpression of ΔZinc Fingers led to the appearance of several slower migrating DYRK1A bands similar to full-length TRAF2 (see input Flag-DYRK1A and Myc-IP Flag-DYRK1A panels). These observations suggested that its TRAF domain is involved in TRAF2 interaction with DYRK1A. Furthermore, E3 ligase activity mediated through RING domain is required for the generation of the slower DYRK1A migrating signals, presumably, ubiquitinated DYRK1A.

TRAF2 recognizes a major ((P/S/A/T)x(Q/E)E) and minor (PxQxxD) motif for binding [37]. DYRK1A protein has two candidate TRAF2-binding motif sites: 583PVQE586 and 708PRQE711 (Fig. 2C). A sequence comparison of the potential TRAF2 binding from various organisms, including human, mice, frog, and monkeys, showed that the major sites are conserved in vertebrates (Fig. 2D); however, it is not present in insects or nematodes (data not shown).

We tested the significance of these two sites for interaction and found that DYRK1A PVQE/AAAA and PVQE-PRQE/AAAA-AAAA mutant proteins have significantly lower ability to interact with TRAF2, whereas DYRK1A PRQE/AAAA mutation alone does not alter the interaction significantly compared to wild-type (WT) DYRK1A (Fig. 2E). Moreover, TRAF2 overexpression did not cause the appearance of slower migrating bands in DYRK1A PVQE/AAAA mutant protein and in DYRK1A PVQE-PRQE/AAAA-AAAA mutant protein. Taken together, the above experiments suggest that TRAF2 interacts with DYRK1A through its TRAF domain and binds to its binding motif PVQE on DYRK1A.

TRAF2 mediates K63-linked ubiquitination of DYRK1A
We had observed that overexpression of TRAF2 did not significantly affect the protein level of overexpressed DYRK1A and endogenous DYRK1A but caused retarded migration of DYRK1A on SDS-PAGE (Figs. 1C Input, 1D Input, 2B Input, and 3A). These additional signals were abolished in E3 Ligase activity-deficient ΔRING TRAF2 mutant (Figs. 2B Input and 3A).
DYRK1A and TRAF2 interacted by binding to TRAF domain-binding motif "PVQE" on DYRK1A. A Schematic representation of TRAF2 and its truncations. All constructs are Myc-tagged at N terminus. B TRAF2 domains mediating interaction with DYRK1A. Myc-TRAF2 and Myc-TRAF2 deletion constructs were affinity purified from cells co-transfected with Flag-DYRK1A and probed with α-Myc and α-Flag antibodies. All TRAF2 constructs, except ΔTRAF, immunoprecipitated Flag-DYRK1A. C Sequence alignment of the major TRAF2-binding motif shows sequence conservation on DYRK1A. Conserved motif is the major TRAF2-binding motif. Schematic representation of DYRK1A with putative TRAF2-binding motifs. D Flag-DYRK1A, Flag-DYRK1A-PVQE/AAAA, Flag-DYRK1A-PRQE/AAAA, and the double mutant were co-expressed with Myc-TRAF2, Flag-affinity purified, and probed with α-Myc antibody. Flag-DYRK1A-PVQE/AAAA and the double mutant have significantly diminished ability to pull down TRAF2.

We analyzed if overexpression or knockdown of TRAF2 affected bulk levels of endogenous DYRK1A protein and found no significant changes (Fig. 3B). TRAF2 mediates K63-linked or K48-linked ubiquitination of its substrates [20–23, 38, 39]. We therefore assessed whether DYRK1A could be ubiquitinated by TRAF2 and what is the nature of its linkage. To determine the nature of the linkage, we first co-transfected WT Myc-tagged Ub (WT Myc-Ub) or Myc-Ub, which has all lysines mutated to alanine, except K63 (K63-only Myc-Ub) along with Flag-DYRK1A and/or HA-TRAF2, and performed Flag affinity purification to enrich DYRK1A and analyze its ubiquitinated forms. Overexpression of "K63-only Myc-Ub," but not "K48-only Myc-Ub," lead to the appearance of ~120 kDa signal. Moreover, the signal intensity increased when TRAF2 was co-expressed along with WT Myc-Ub (Fig. 3C lane 6), and increased further, with "K63-only Myc-Ub" (Fig. 3C lane 8). This suggested that a fraction of cellular DYRK1A could be K63 ubiquitinated and TRAF2 can mediate this modification. Therefore, we co-expressed WT Myc-Ub, K48R Myc-Ub, or K63R Myc-Ub along with Flag-DYRK1A and/or HA-TRAF2. Enriched Flag-DYRK1A showed strong ubiquitin signal in the presence of WT Myc-Ub and K48R Myc-Ub (Fig. 3D lanes 6 and 7), but not in K63R Myc-Ub (Fig. 3D lane 8), and thus we verified that the ~120 kDa signal is indeed K63-ubiquitinated DYRK1A. Interestingly, we found that TRAF2 ΔRING mutant completely abrogated DYRK1A ubiquitination (Fig. 3E lane 4) and TRAF2 ΔTraf mutant (Fig. 3E lane 5) had significantly lower ability to ubiquitinate DYRK1A compared to WT TRAF2 (Fig. 3E lane 3). Moreover, increasing amounts of TRAF2 expression caused increased ubiquitination level of endogenous DYRK1A in a dose-dependent manner (Fig. 3F). To further confirm whether TRAF2 is a direct ubiquitin E3 ligase for DYRK1A, we performed in vitro ubiquitination assay in the presence of recombinant human GST-TRAF2 and purified Flag-DYRK1A. Remarkably, TRAF2 was able to ubiquitinate DYRK1A in vitro (Fig. 3G). Taken together, these results suggest that TRAF2 promotes K63-linked ubiquitination of a partial pool of cellular DYRK1A.

TRAF2 is critical for translocation of DYRK1A to a detergent-insoluble fraction
K63-linked ubiquitination has been linked to a number of functions including signal transduction, protein trafficking, protein–protein interaction, and DNA damage response. TRAF2-mediated K63-linked ubiquitination has been shown to function in protein–protein interaction and enzymatic activity [20–23]. To gain insight into the potential effects of TRAF2 on DYRK1A function, and if TRAF2 promotes translocation of DYRK1A to endocytic vesicles or endosomes, we generated Triton X-100 (0.5%)-soluble and -insoluble fractions. The soluble fraction contains the majority of soluble cytoplasmic and nuclear proteins, whereas cytoskeletal and vesicles remain in the insoluble fraction. A fraction of TRAF2 localizes to the Triton X-100-insoluble fraction [40–42]. Further, it has been reported that a cellular pool of DYRK1A is located in Triton X-100-resistant manner [12] and interacts with a number of vesicular proteins, including Sprouty 2, Synaptojanin 1, Amphiphysin, Dynamin 1, Endophilin 1, and phosphotyrosylates several of them [12, 13, 43, 44]. After TRAF2 overexpression, we found that a significant amount of endogenous DYRK1A became sequestered into the insoluble fraction (Fig. 4A). Further, increasing amounts of TRAF2 expression caused increased migration of endogenous DYRK1A to detergent-insoluble fraction in a dose-dependent manner (Fig. 4B).
To further understand the dependency of this phenomenon on TRAF2 dosage and to avoid drawing conclusions based mainly on overexpression experiments, we analyzed localization of endogenous DYRK1A after reducing TRAF2 by shRNA in multiple cell lines. Knockdown of TRAF2 in HEK293 cells with two different shRNAs consistently increased the DYRK1A protein in the soluble fraction (Fig. 4C). Similar results were obtained in SH-SY5Y cells (data not shown). These observations suggest that TRAF2 is critical for translocation of DYRK1A into membranous vesicles and is probably a common phenomenon in various tissues.

To dissect the domain of TRAF2 responsible for DYRK1A translocation, we analyzed the effects of overexpressing TRAF2 truncations in HEK293 cells. DYRK1A was translocated to detergent-insoluble fraction when TRAF2-WT or the ΔZinc Fingers were overexpressed. In contrast, the ΔRING or ΔTRAF mutants failed to induce translocation of endogenous DYRK1A to insoluble fraction.
Fig. 4  TRAF2 is critical for translocation of DYRK1A to a detergent-insoluble fraction. A Distribution of DYRK1A in soluble and insoluble fractions. HEK293 cells transfected with Myc-TRAF2 were lysed in Tris buffer containing 0.5% Triton X-100, and soluble and insoluble fractions were separated by centrifugation. Whole-cell lysates were prepared by directly lysing the cells in SDS loading buffer. B DYRK1A distribution in soluble and insoluble fractions with increasing expression of TRAF2. Increasing amounts of Myc-TRAF2 were transfected and cells fractionated to obtain soluble and insoluble fractions as in A. With increasing amounts of TRAF2, soluble DYRK1A decreases, whereas the insoluble fraction increases. C Knockdown of TRAF2 affects distribution of DYRK1A in soluble and insoluble fractions. TRAF2 was silenced using two different shRNAs and cells fractionated. Amount of DYRK1A in the soluble fraction increases upon TRAF2 knockdown, whereas it decreases in the insoluble fraction. Also, the effect depends on the efficiency of TRAF2 silencing. Right panel shows quantification of three independent experiments. Data were shown as mean ± SD, *P < 0.05 and **P < 0.01. D Analysis of TRAF2 domains responsible for distribution of DYRK1A to soluble and insoluble fractions. TRAF2 truncates and full-length TRAF2 were transfected in HEK293 cells, and cells fractionated. The presence of endogenous DYRK1A in soluble and insoluble fractions were determined. RING domain and TRAF domain truncates were unable to translocate DYRK1A to insoluble fraction. E Analysis of TRAF2 domains responsible for distribution of exogenous DYRK1A to soluble and insoluble fractions. Exogenous Flag-DYRK1A was transfected additionally to the D experiment and distribution of Flag-DYRK1A probed. F Analysis of distribution of Flag-DYRK1A-PVQE/AAAA in soluble and insoluble fractions. Lentiviruses were used to express Flag-DYRK1A in HEK293 cells and their distribution analyzed after overexpression of TRAF2. Flag-DYRK1A-PVQE/AAAA does not translocate to insoluble fraction as efficiently as WT DYRK1A.
TRAF2 promotes DYRK1A-mediated phosphorylation of SPRY2. A Interaction analysis between DYRK1A and SPRY2 in the presence of WT TRAF2 or its truncates. V5-SPRY2 was co-transfected with Flag-DYRK1A, Myc-TRAF2, or its different truncations into HEK293T cells and Flag-affinity purified. Immunoprecipitates were probed with α-Flag and α-V5 to analyze the enrichment of SPRY2 in DYRK1A pulldowns after overexpression of TRAF2 and truncates. B Analysis of phosphorylation status of SPRY2 in the presence of DYRK1A and TRAF2. V5-SPRY2 was co-transfected with Flag-DYRK1A (WT, PVQE/AAAA or K188R) and/or Myc-TRAF2 (WT, ΔRING or ΔTRAF) in HEK293T cells, followed by V5-affinity purification. Immunoprecipitates were probed with α-phospho-pan-Ser/Thr antibody. Full-length TRAF2, but not ΔRING or ΔTRAF deletions, was able to promote phosphorylation of SPRY2 in the presence of wild-type DYRK1A. Also, Flag-DYRK1A-PVQE/AAAA mutant did not promote the phosphorylation of SPRY2. C Cellular localization of V5-SPRY2, Myc-TRAF2, Flag-DYRK1A, and Rab5. HEK293T cells were co-transfected with V5-SPRY2, Flag-DYRK1A, and/or Myc-TRAF2, and immunostained with respective antibodies. Images were acquired using ZEISS 710 confocal laser scanning microscope. The first three panels, scale bar = 25 μm. The last panel, scale bar = 1 μm.
Further, we asked whether the TRAF2-binding motif PVQE sequence present on DYRK1A protein is required for translocation of DYRK1A to detergent-insoluble fraction. We used an inducible lentiviral vector to express DYRK1A WT or PVQE/AAAA mutant in HEK293 cells and observed that upon TRAF2 overexpression, PVQE/AAAA mutant remained mostly soluble compared to WT DYRK1A (Fig. 4F, compare lanes 4 and 6 with lanes 10 and 12). These findings suggest that TRAF2 causes translocation of DYRK1A to a detergent-insoluble fraction, likely by ubiquitinating it.

**TRAF2 promotes phosphorylation of SPRY2 by DYRK1A**

Translocation of ubiquitinated DYRK1A into vesicles, where it can potentially phosphorylate multiple proteins, suggests that DYRK1A might have a widespread role in vesicle biology. DYRK1A has been shown to regulate synaptic vesicle endocytosis and recycling in Drosophila as well as in mammalian system [11, 43]. DYRK1A phosphorylates a number of proteins in the vesicles, including SPRY2, Synaptojanin 1, Endophilin 1, and Dynamin 1. To understand the direct impact of ubiquitinated DYRK1A in the vesicles, we briefly scanned some of the known DYRK1A substrates in vesicles, including SPRY2, Synaptojanin 1, Dynamin 1, and α-synuclein for an increase in phosphorylation; however, due to absence of readily available antibodies specific to phosphorylated forms of these proteins, we are unable to build a detailed map of substrates of ubiquitinated DYRK1A. We chose to further investigate SPRY2 and determine whether it is one of the substrates of ubiquitinated DYRK1A.

DYRK1A has been shown to phosphorylate SPRY2 on Thr75, and possibly other sites [45, 46], which in turn prevents endocytotic degradation of EGFR [16, 17]. We first asked whether TRAF2 can promote the interaction of DYRK1A with SPRY2. We co-expressed VS-SPRY2, Flag-DYRK1A, and/or MYC-TRAF2 (WT, ΔRING, and ΔTRAF) in HEK293T cells and affinity-purified Flag-DYRK1A, then analyzed the enrichment of SPRY2. We observed that V5-SPRY2 was more enriched in Flag-DYRK1A eluates when co-transfected with WT TRAF2 (lane 4), compared to empty vector (lane 2), ΔRING (lane 5), and ΔTRAF (lane 6) mutants (Fig. 5A), suggesting that the translocation of ubiquitinated DYRK1A into vesicles enabled increased interaction between DYRK1A and SPRY2. We further tested whether phosphorylation of SPRY2 could be promoted by TRAF2. We co-transfected V5-SPRY2 along with various constructs of DYRK1A and TRAF2, affinity-purified V5-SPRY2, and analyzed its phosphorylation status. We found that WT TRAF2, but not RING domain deletion or TRAF domain deletion, increased the phosphorylation level of Sprouty 2 (Fig. 5B lanes 5, 10, and 11). Flag-DYRK1A-PVQE/AAAA mutant also did not promote the phosphorylation of SPRY2 (Fig. 5B lanes 8 and 9). The catalytically inactive Flag-DYRK1A (K188R mutant) could not phosphorylate SPRY2 with/without TRAF2 overexpression (Fig. 5B lanes 6 and 7).

To further analyze the cellular colocalization of DYRK1A, TRAF2, and SPRY2, we performed confocal microscopy in HEK293T cells. TRAF2 localizes within a number of cellular structures, including the cytoplasm, lipid rafts in the plasma membrane [47], mitochondria [48, 49], and endoplasmic reticulum [42]. Over-expressed TRAF2 also localizes to the vesicles, in both mouse and human cells [50]. As reported previously, SPRY2 showed a diffused cytoplasmic staining (Fig. 5C) [51], whereas overexpressed Flag-DYRK1A showed strong nuclear staining and weak cytoplasmic staining (Fig. 5C) [52]. Upon co-expression of V5-SPRY2, Myc-TRAF2, and Flag-DYRK1A, we observed colocalization of V5-SPRY2 and DYRK1A in the vesicles (Fig. 5C). Further, we found that some of the vesicles can colocalize with endosome marker Rab5 (Fig. 5C). These experiments suggest that TRAF2 can promote the interaction of DYRK1A with SPRY2 and thus promote the phosphorylation of SPRY2 by DYRK1A.

**Depletion of DYRK1A inhibits the growth of glioma cells mediated by TRAF2**

Recent reports show that TRAF2 is of prognostic significance in glioblastoma and its inhibition suppresses proliferation of glioblastoma cells [28, 29]. To examine whether TRAF2-promoted proliferation of glioblastoma cells is mediated through DYRK1A, we first performed shRNA-mediated knockdown of DYRK1A using lentiviruses (Fig. 7A). We also inhibited DYRK1A kinase activity using two different DYRK1A inhibitors INDY and Harmine (Fig. 7B). Both the treatments significantly suppressed the growth and colony-forming capacities of U251 cells (Fig. 7B, C). Also, DYRK1A inhibition resulted in a significant reduction in the rate of cell migration compared to the control (Fig. 7D). As has been previously suggested [17], our results also show that DYRK1A inhibition suppresses the growth and migration of
glioma cells. We then overexpressed TRAF2 in DYRK1A-silenced A172 cells and observed that TRAF2 cannot rescue the growth inhibition caused by DYRK1A knockdown (Fig. 7E, F). These results imply that DYRK1A is an important downstream target of TRAF2 in glioma cells.

**DISCUSSION**

Understandings of DYRK1A functions has steadily increased in the past two decades and we currently know more than 20 substrates that can be phosphorylated by DYRK1A in various cellular compartments. DYRK1A is a highly conserved protein in
vertebrates and contains a kinase domain, a DYRK1A homology (DH) domain, two nuclear localization signals, a PEST region, a histidine-rich domain, and C-terminal region rich in serine and threonine [44]. These domains may interact with proteins that cause translocation of DYRK1A to various sites within a cell. Whether these domains directly or indirectly regulate the kinase activity of DYRK1A is a very important question. Earlier studies demonstrated that DYRK1A is auto-activated by autophosphorylation of the critical activation-loop tyrosine during translation [55], and that the phosphorylation of SS20 could promote the kinase activity further by allowing the binding of 14-3-3 [56]. A more recent study of the structure of Dyrk family of kinases has implicated the DH domain and NAPA region in its kinase activity [57]. Therefore, it is likely that auto-activation allows DYRK1A to phosphorylate some or many substrates within the cell, whereas interaction with other proteins may either promote its interaction with other substrates or regulate its translocation to subcellular compartments [56]. Therefore, an important mode of regulation of kinase activity of DYRK1A could be compartmentalization. DYRK1A has been shown to be localized in many different cellular organelles, where it may phosphorylate its substrates. In vesicles, DYRK1A phosphorylates SPRY2, Synaptojanin 1, Dynamin 1, and probably other proteins.

In this study we show that DYRK1A is posttranslationally modified by TRAF2, an important adaptor molecule and an E3 ligase of the TNFα receptor superfamily. Our data suggests that TRAF2 interacts with a partial pool of cytoplasmic DYRK1A, binds to its "PVQE"-binding motif, and performs its K63-linked ubiquitination (Fig. 3C, D). Using the PVQE-binding site mutant and TRAF2 RING domain mutant, we demonstrated that K63-linked ubiquitination is key for the translocation of DYRK1A to the vesicles, present in the Triton X-100-insoluble fractions (Fig. 4D, F). To analyze whether this translocation is a general phenomenon in various cellular contexts, and if it occurs endogenously, we have analyzed the translocation of DYRK1A after knocking down TRAF2 in two different cell lines. Both cells showed increased translocation of DYRK1A from insoluble to soluble fraction. This significant change in the DYRK1A localization after TRAF2 knockdown suggests that a sizable fraction of DYRK1A is ubiquitinated and translocated to the endosome, and possibly to other membrane-bound fractions.

Our study provides a mechanistic understanding of how DYRK1A is translocated to these vesicular structures and regulates processes mediated through vesicles and the endocytic system through TRAF2 (Fig. 8). Although TRAF2 is very well-studied, its function in signaling pathways other than the TNFα pathway is barely understood. Recent studies have begun to unravel the role of TRAF2 in cancers, including in the glioma [29]. To the best of our knowledge, regulation of EGFR stability by TRAF2 has not yet been reported. It is interesting to know that there could be a link between TRAF2, an important adaptor molecule of the TNFα pathway and EGFR. It raises some important questions, including if TNFα pathway can regulate the EGFR pathway and in what contexts. Also, it would be interesting to know whether activation of the non-canonical NF-κB pathway by CD40, BAFF receptor, lymphotixin-β receptor, or other inducers, which lead to degradation of TRAF2 [19], affect the ubiquitination status and localization of DYRK1A, and if the TRAF2–DYRK1A–SPRY2 axis can mediate stabilization of EGFR and activation of the EGFR-signaling pathway. The addition of TRAF2 to the DYRK1A–SPRY2–EGFR axis has broadened the complexity of regulation of EGFR and its dynamics in cancer signaling.

REFERENCES

1. Becker W, Sippl W. Activation, regulation, and inhibition of DYRK1A. FEBS J. 2011;278:246–56.
2. Arbones ML, Thomazeau A, Nakano-Kobayashi A, Hagiwara M, Delabar JM. DYRK1A and cognition: a lifelong relationship. Pharm Ther. 2019;194:199–221.
3. Fernández-Martínez P, Zahonero C, Sánchez-Gómez P. DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis. Mol Cell Oncol. 2015;2:e570048.
4. Earl RK, Turner TN, Mefford HC, Hudac CM, Gerds T, Eichler EE, et al. Clinical phenotype of ASD-associated DYRK1A haploinsufficiency. Mol Autism. 2017;8:54.
5. Evers JM, Laskowski RA, Bertolli M, Clayton-Smith J, Deshpande C, Eason J, et al. Structural analysis of pathogenic mutations in the DYRK1A gene in patients with developmental disorders. Hum Mol Genet. 2017;26:519–26.
6. Fotaiki V, Dierssen M, Alcántara S, Martínez S, Martí E, Casas C, et al. DYRK1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol Cell Biol. 2002;22:6636–47.
7. Fotaiki V, Martínez De Lagrán M, Estivill X, Arbonés M, Dierssen M. Haploinsufficiency of DYRK1A in mice leads to specific alterations in the development and regulation of motor activity. Behav Neurosci. 2004;118:815–21.
8. Tejedor F, Zhu XR, Kaltenbach E, Ackermann A, Baumann A, Canal I, et al. Mini-brain: a new protein kinase family involved in postembryonic neurogenesis in Drosophila. Neuron. 1995;14:287–301.
9. Kim OH, Cho HI, Han E, Hong TI, Ariyasiri K, Choi JH, et al. Zebrafish knockout of Down syndrome gene, DYRK1A, shows social impairments relevant to autism. Mol Autism. 2017;8:50
10. Guedj F, Sbréci C, Rivals I, Ledru A, Paly E, Bizot JC, et al. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS ONE. 2009;4:e4606.

11. Kim Y, Park J, Song WJ, Chang S. Overexpression of DYRK1A causes the defects in synaptic vesicle endocytosis. Neurogenetics. 2010;11:164–72.

12. Munakami N, Bolton D, Hwang YW. DYRK1A binds to multiple endocytic proteins required for formation of clathrin-coated vesicles. Biochemistry. 2009;48:2997–2997.

13. Munakami N, Bolton DC, Kida E, Xie W, Hwang YW. Phosphorylation by DYRK1A of clathrin coated vesicle-associated proteins: identification of the substrate proteins and the effects of phosphorylation. PLoS ONE. 2012;7:e34845.

14. Munakami N, Xie W, Lu RC, Chen-Hwang MC, Wierzakoski A, Hwang YW. Phosphorylation of amphiPhosphin I by minibrain kinase/dual-specificity tyrosine phosphorylation-regulated kinase, a kinase implicated in Down syndrome. J Biol Chem. 2006;281:23712–24.

15. Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, Gurbuxani S, et al. Increased dosage of the chromosome 21 ortholog DYRK1A promotes mega-karyoblastic leukemia in a murine model of Down syndrome. J Clin Invest. 2012;122:948–62.

16. Ferron SR, Pozo N, Laguna A, Aranda S, Porlan E, Moreno M, et al. Regulated segregation of kinase DYRK1A during asymmetric neural stem cell division is critical for EGFR-mediated biased signaling. Cell Stem Cell. 2010;7:367–79.

17. Pozo N, Zahonero C, Fernández P, Liñares JM, Ayuso A, Hagihara M, et al. Inhibition of DYRK1A destabilizes EGR and reduces EGR-dependent glioblastoma growth. J Invest Investig. EMBO J. 2005;24:1886–98.

18. Kaczmerski W, Barua M, Mazur-Kolecka B, Frackowiak J, Dowjat W, Mehta P, et al. Phosphorylation by Dyrk1A of ribonucleoprotein D-like promotes the growth of human colon cancer SW620 cells via its regulation of cell cycle. Acta Biochim Biophys Sin. 2018;50:880–890.

19. Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, Núñez G, et al. A critical mechanism for TRAF functions. Immunol Rev. 2015;266:56–75.

20. González F, Lawrence D, Yang B, Yee S, Pitti R, Masters S, et al. TRAF2 sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff motif. Mol Cell. 2012;48:888–99.

21. Robeson AC, Lindblom KR, Wojton J, Kombuhl S, Matsurra K. Dimer-specific immunoprecipitation of active caspase-2 identifies TRAF proteins as novel activators. EMBO J. 2018;37:e97072.

22. Wang B, Jie Z, Joo D, Ordureau A, Liu P, Gan W, et al. TRAF2 and OTUD7B govern ERK signalling in health and disease. F1000Res. 2019;8:1000.

23. Peramuhendige P, Marino S, Bishop RT, de Ridder D, Khogeer A, Baldini I, et al. The LIM protein Ajuba recruits DBC1 and CBP/p300 to acetylate Eralpapa and enhances Eralpapa target gene expression in breast cancer cells. Nucleic Acids Res. 2014;42:7124–34.

24. Yoshida H, Kitamura Y, Tsuchiya H, Tanaka Y, Minamino N, et al. Phosphorylation of DYRK1A by Dyrk1A maintains Akt activity in the heart. J Biol Chem. 2006;281:23712–24.

25. Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, Gurbuxani S, et al. Increased dosage of the chromosome 21 ortholog DYRK1A promotes mega-karyoblastic leukemia in a murine model of Down syndrome. J Clin Invest. 2012;122:948–62.

26. Feng L, Pan C, Chao Z, Han Q, Zheng J, Xing H, et al. The zinc finger protein A20 targets TRAF2 to the clathrin coated vesicle-associated proteins: identiﬁcation of the substrate proteins and the effects of phosphorylation. PLoS ONE. 2012;7:e34845.

27. Zhang W, Sun Y, Liu L, Geng M, Guo W, Xue Y, et al. Regulation of the substrate pro-activation of the substrate pro-activiation of the substrate phosphorylation by Dyrk1A. J Neurosci Res. 2014;92:162–73.

28. Yang XD, Sun SC. Targeting signaling factors for degradation, an emerging mechanism for TRAF functions. Immunol Rev. 2015;265:56–71.

29. González F, Lawrence D, Yang B, Yee S, Pitti R, Masters S, et al. TRAF2 sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff motif. Mol Cell. 2012;48:888–99.

30. Robeson AC, Lindblom KR, Wojton J, Kombuhl S, Matsurra K. Dimer-specific immunoprecipitation of active caspase-2 identifies TRAF proteins as novel activators. EMBO J. 2018;37:e97072.

31. Wang B, Jie Z, Joo D, Ordureau A, Liu P, Gan W, et al. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling. Nature. 2017;545:365–369.

32. Yang CHY, Chiu LL, Tan TH. TRAF2-mediated Lyn:63-linked ubiquitination of DUSP14/MKP6 is essential for its phosphatase activity. Cell Signal. 2016;28:145–141.

33. Sauerbier M, Nicolaou N, Gurnani S, Desai M, Roberson AC, Lin AE, et al. TRAF2 multiskinting in TNF receptor-induced signaling to NF-kappaB, MAP kinases and cell death. Biochem Pharmac. 2016;116:1–10.

34. Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, Núñez G, et al. Critical role of RICK/RIP2 ubiquitylation in nod-activated NF-kappaB activation. EMBO J. 2008;27:3733–43.

35. Mickiewicz SS, Jessen FR, SB, Chiliveru S, Melchjorsen J, Julkunen I, Gaestel M, et al. RIG-I-mediated activation of p38 MAPK is essential for viral induction of interferon and activation of dendritic cells: dependence on TRAF2 and TAK1. J Biol Chem. 2009;284:10774–82.

36. Peramuhendige P, Marino S, Bishop RT, de Ridder D, Khogeer A, Baldini I, et al. TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis. Cell Death and Disease. 2021;12:608.

37. Zhang W, Sun Y, Liu L, Liu Z. Prognostic Significance of TNFR-Associated Factor 1 and 2 (TRAF1 and TRAF2) in Glioblastoma. Med Sci. 2017;3:4506–12.

38. Zheng M, Morgan-Lappe SE, Yang J, Bockbrader KM, Pambrathy D, Thomas D, et al. Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor-2. Cancer Res. 2008;68:7570–7578.

39. Connors M, Li J, Su K, Yang J, Xiong X, et al. DYRK1A interacts with histone acetyl transferase p300 and CBP and localizes to enhancers. Nucleic Acids Res. 2018;46:11202–13.

40. Zhang P, Ji D, Hu X, Ni H, Ma W, Zhang X, et al. Oncogenic heterogenous nuclear ribonucleoprotein D-like promotes the growth of human colon cancer SW620 cells via its regulation of cell-cycle. Acta Biochim Biophys Sin. 2018;50:880–887.

41. Xu X, Li J, Chen N, Zhu J, Meng G, Ayaganathan K, et al. The LIM protein Ajuba recruits DBC1 and CBP/p300 to acetylate Eralpapa and enhances Eralpapa target gene expression in breast cancer cells. Nucleic Acids Res. 2019;47:23222–35.

42. Mohan M, Hez HM, Takahashi YH, Lin C, Lai KC, Zhang Y, et al. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 2010;24:574–89.

ACKNOWLEDGEMENTS

We thank Drs Xiaodong Yang and Fubin Li for helpful discussions.
AUTHOR CONTRIBUTIONS
P.Z. designed the study, performed the experiments, analyzed the data, and drafted the manuscript. Z.Z. and Y.F. contributed to some technical support and analyzed the data. Y.Z., M.P.W., and L.F. contributed to experimental operation and statistical analysis. M.W. discussed the results and revised the manuscript. M.M., Z.H., and C.H. conceived the project, designed the study, analyzed and interpreted the data, and revised and finalized the manuscript. All authors read and approved the final manuscript.

FUNDING
This work was supported in part by Major Basic Research Project of Science and Technology of Yunnan (202001BC070001) to LPBR, and in part by National Natural Science Foundation of China (31471206) to M.M., by Project funded by China Postdoctoral Science Foundation to P.Z. Y.Z., M.P.W., and L.F. are supported by The Stowers Institute for Medical Research.

ETHICS STATEMENT
Not applicable. No human or animal data and experiments are involved in the study.

Conflict of interest
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to C.H., Z.H. or M.M.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021